2024-515166-14-00招募中3 期
BASIC - Botulinum toxin type A blockade of the sphenopalatine ganglion in treatment-refractory chronic cluster headache
Norwegian University Of Science And Technolology3 个研究点 分布在 2 个国家目标入组 49 人开始时间: 2024年11月7日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 49
- 试验地点
- 3
- 主要终点
- Difference in change from the last 28 day period of the baseline in mean number of cluster headache attacks per week at weeks 5 – 8 post-intervention in the treatment group versus the placebo group.
研究概览
简要总结
This project aims to determine the efficacy of botulinum toxin towards the sphenopalatine ganglion (SPG) in treatment of refractory chronic cluster headache using an image-guided surgical device (MultiGuide®).
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Informed and written consent.
- •Ability to understand study procedures and to comply with them for the entire length of the study
- •Male or female, 18-85 years of age
- •Headache attacks fulfilling the International Classification of Headache Disorders (ICHD) III criteria for chronic cluster headache (CCH) 3.1.
- •Dominant headache laterality with ≥ 80% of cluster headache attacks on one side.
- •Subject reports an average of ≥ 4 cluster attacks/week on the side of their dominant headache laterality in the 3 months prior to inclusion and in the baseline period.
- •The condition is pharmacologically refractory defined as suboptimal effect or intolerable side effects or contraindication for verapamil or lithium or suboccipital steroid injection.
- •Subject agrees to maintain current preventive headache medication regimens (no change in type, frequency, or dose) during the whole study period.
- •Subject is able to differentiate concomitant headaches from cluster headache.
- •In case of women of childbearing potential (WOCBP) they have to be using highly effective contraception in a period of 4 weeks after injection.
排除标准
- •Subject has had a change in type, dosage or dose frequency of preventive headache medications ≥ two weeks prior to baseline/screening or 5 half-lives, whichever is longer.
- •Use of opioids for ≥10 days per month.
- •Treatment with pharmacological substances that may interact with BTA (aminoglycosids, spectinomycin, neuromuscular blockers, both depolarizing agents (such as succinylcholine) or non-depolarizing (tubocurarine derivates), lincosamides, polymyxins, quinidine, magnesium sulfate or anticholinestases.).
- •WOCBP that do not adhere to the requirements for HEC, as noted in inclusion criteria 9 and outlined in section 3.
- •Pregnancy or breastfeeding in the study period
- •ubject has undergone facial surgery in the area of the pterygopalatine fossa or zygomaticomaxillary buttress ipsilateral to the planned injection site that, in the opinion of the Investigator, may lead to an inability to properly conduct the procedure.
- •Facial anomaly or trauma which renders the procedure difficult.2
- •Subject currently has an active oral or dental abscess or a local infection at the site of injection based on present symptoms.
- •Subject has been diagnosed with any major infectious processes such as osteomyelitis, or primary or secondary malignancies involving the face that have been active or required treatment in the past 6 months.
- •Patients exhibiting a high degree of comorbidity and/or frailty associated with reduced life expectancy or high likelihood of hospitalization, at the discretion of the investigator.
- •Patients with comorbid psychiatric disorders with psychotic or other symptoms making compliance with the study protocol difficult, at the discretion of the investigator.
- •Subject currently treated with occipital nerve stimulation, deep brain stimulation or other implantable device, that have changed parameters in the last month, or are unable to keep parameters stable throughout the study.
- •Patient with active infectious disease or infections that warrants special infection control measures, such as human immunodeficiency virus, tuberculosis, or chronic hepatitis B or C infection.
- •Patient with disorders that are known contraindication for Botox® treatment, especially neuromuscular disorders such as motorneuron disorders and myasthenic syndromes
- •Subject has had previous radiofrequency ablation, balloon compression, gamma knife, or chemical denervation (e.g. glycerol treatments) of the ipsilateral trigeminal ganglion or any branch of the trigeminal nerve.
- •Subject has had previous radiofrequency ablation (including non-lesional pulsed radiofrequency), balloon compression, gamma knife, or chemical denervation (e.g. glycerol treatments) of the ipsilateral SPG.
- •Subject has had blocks of short-acting anaesthetics of the ipsilateral SPG in the last 3 months.
- •Subject has undergone onabotulinumtoxinA injections of the head and/or neck in the last 3 months.
- •Subject is anticipated to require any excluded medication, device, or procedure during the study.
- •Subject has a history of bleeding disorders and in the opinion of the Investigator, may lead to an inability to properly conduct the procedure.
- •Subject has a history of coagulopathy
- •Subject is unable to stop antithrombotic medication, eg. anticoagulants and/or antiplatelet therapy, before procedure.
- •Current or previous treatment with implanted medical devices targeting the SPG
- •The subject has been diagnosed with another trigeminal autonomic cephalalgia or trigeminal neuralgia.
- •The patient cannot participate or successfully complete the study, in the opinion of their healthcare provider or the investigator, for any of the following reasons: • mentally or legally incapacitated or unable to give consent for any reason. • in custody due to an administrative or a legal decision, under tutelage, or being admitted to a sanatorium or social institution.
- •The patient is a study centre employee who is directly involved in the study or the relative of such an employee.
- •Subject has had a change in type, dosage or dose frequency of preventive headache medications during the baseline period, eg. prior to IMP administration.
- •Non-responder to both oxygen and triptan.
- •Participation in a clinical study of a new chemical entity or a prescription medicine within 2 months before study drug administration or 5 half-lives, whichever is longer
- •Subject is currently participating or has participated in the last 3 months in another clinical study in which the subject has, is, or will be exposed to an investigational or non- Basic Study Protocol, Version 3.0, 18.06.2023 17 investigational drug or device.
- •Allergy or hypersensitivity reactions to marcaine, lidocaine, xylocaine, adrenaline, any botulinum toxin or similar substance
- •Abuse of drugs or alcohol.
结局指标
主要结局
Difference in change from the last 28 day period of the baseline in mean number of cluster headache attacks per week at weeks 5 – 8 post-intervention in the treatment group versus the placebo group.
Difference in change from the last 28 day period of the baseline in mean number of cluster headache attacks per week at weeks 5 – 8 post-intervention in the treatment group versus the placebo group.
次要结局
- Difference in occurrence of AEs and SAEs in the active group versus the placebo group
- Difference in change from baseline week 5-8 in mean number of cluster headache attacks per week during weeks 9-12 post-intervention in the active group versus the placebo group
- Difference in change from baseline week 5-8 in mean number of cluster headache attacks per week at weeks 5-8 post-intervention in the active group versus the placebo group, in the prespecified subgroups (cf 8.4.1.2) 3.1. In the high and the low frequency subgroups 3.2. In the high and the low frequency variation subgroups
- Difference in change from baseline week 5-8 in mean number of cluster headache attacks per week during weeks 9-12 post-intervention in the active group versus the placebo group, in the prespecified subgroups (cf 8.4.1.2) 4.1. In the high and the low frequency subgroups 4.2. In the high and the low frequency variation subgroups
- Difference in the number of therapeutic responders (≥ 30% reduction in attack frequency, intensity or both during weeks 5 – 8 post-intervention compared to baseline) in the active group versus the placebo group. 5.1. In the entire randomized population 5.2. In the high and the low frequency subgroups 5.3. In the high and the low frequency variation subgroups
- Difference in the number of attack frequency responders (≥ 30% reduction in attack frequency during weeks 5 – 8 post-intervention compared to baseline). 6.1. In the entire randomized population 6.2. In the high and the low frequency subgroups 6.3. In the high and the low frequency variation subgroups
- Difference in change from baseline week 5-8 in mean attack intensity week 5 – 8 post-intervention in the active group versus the placebo group. 7.1. In the entire randomized population 7.2. In the high and the low frequency subgroups 7.3. In the high and the low frequency variation subgroups
研究者
Coordinating investigator
Scientific
Norwegian University Of Science And Technolology
研究点 (3)
Loading locations...
相似试验
Unknown
不适用
The Sphenopalatine Ganglion Block for Post-dural Puncture HeadachePost-Dural Puncture HeadacheNCT03385772Brigham and Women's Hospital20
已完成
3 期
Blocking Sphenopalatine Ganglion by Intranasal Lidocaine Spray in Partial Turbinectomy SurgeriesNCT07299630Ain Shams University50
尚未招募
2 期
Sphenopalatine Ganglion Stimulation – Proof-of-Concept in the Treatment of Delayed Cerebral Ischemia due to Aneurysmal Subarachnoid HemorhageI67.8Other specified cerebrovascular diseasesDRKS00027984niversitätsklinikum Düsseldorf10
招募中
不适用
Sphenopalatine Block Versus BOTOX in Management of Chronic MigraineNCT06974617Cairo University64
已完成
不适用
SGB in Management of Patients With PDPH Using TCDPost-Dural Puncture HeadacheNCT04401878Zagazig University120